Landscapes / Companies
PersonGen BioTherapeutics (Suzhou) Co., Ltd. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
3
in active trials · 4 in all
Trials
4 active
8 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 2 | — | |||
| Also tested for | CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma, CD7+ T-ALL/LBL | ||||
| Open drug page | |||||
— |
Phase 1 | 3 Dec 2026soonPhase 1 trial completes | |||
| Next date | 3 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | ||||
| Open drug page | |||||
TAA06not checked |
— |
Phase 1 | — | ||
| Also tested for | B7-H3-positive Relapsed/ Refractory Neuroblastoma | ||||
| Open drug page | |||||
About
- No active trial
- B7-H3 target
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021